SEC Tracker
Get the app

Jazz Pharmaceuticals JAZZ

Jazz Pharmaceuticals reports executive retirement

Form
8-K
Filed
Importance
Routine
  1. Samantha Pearce to retire as Chief Commercial Officer by June 30, 2027
  2. Company to start search for her successor
  3. Pearce notified of retirement intent on October 6, 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Jazz Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  2. Repligen RGEN public float $6.0B, Jun 30, 2025
  3. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025
  4. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  5. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.